US 11,753,400 B2
D-amino acid oxidase inhibitors and therapeutic uses thereof
Guochuan Emil Tsai, Pasadena, CA (US); Ching-Cheng Wang, New Taipei (TW); and Yuan-Ting Hsieh, New Taipei (TW)
Assigned to SyneuRx International (Taiwan) Corp., New Taipei (TW)
Appl. No. 16/757,327
Filed by SyneuRx International (Taiwan) Corp., New Taipei (TW)
PCT Filed Oct. 18, 2018, PCT No. PCT/CN2018/110763
§ 371(c)(1), (2) Date Apr. 17, 2020,
PCT Pub. No. WO2019/076329, PCT Pub. Date Apr. 25, 2019.
Application 16/757,327 is a continuation in part of application No. 15/787,557, filed on Oct. 18, 2017, granted, now 10,336,724, issued on Jul. 2, 2019.
Prior Publication US 2020/0331894 A1, Oct. 22, 2020
Int. Cl. C07D 403/12 (2006.01); A23L 29/00 (2016.01); C07D 401/12 (2006.01); A61K 45/06 (2006.01)
CPC C07D 403/12 (2013.01) [A23L 29/045 (2016.08); C07D 401/12 (2013.01); A61K 45/06 (2013.01)] 15 Claims
 
1. A method for inhibiting D-amino acid oxidase (DAAO) in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:

OG Complex Work Unit Chemistry
X is optionally substituted aryl or optionally substituted heteroaryl;
Y is optionally substituted heteroaryl;
Z is optionally substituted aryl or optionally substituted heteroaryl;
L1 is CH2 or C2-10 alkyl;
L2 is CH2, C2-10 alkyl, or —CH2S,
wherein L2 is bonded to C
or an effective amount of a composition comprising the compound.